CureVac N.V. (5CV.F)
EUR 2.72
(-2.01%)
EUR 2.72
(-2.01%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -234.09 Million EUR | -11.86% |
| 2022 | -209.38 Million EUR | 42.27% |
| 2021 | -386.48 Million EUR | -251.99% |
| 2020 | -123.09 Million EUR | -20.0% |
| 2019 | -91.5 Million EUR | -36.42% |
| 2018 | -69.85 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -68.8 Million EUR | 8.67% |
| 2024 Q1 | -65.6 Million EUR | 11.19% |
| 2023 Q2 | -60.14 Million EUR | -18.11% |
| 2023 FY | - EUR | -11.86% |
| 2023 Q1 | -50.92 Million EUR | 59.71% |
| 2023 Q4 | -81.32 Million EUR | -107.68% |
| 2023 Q3 | -39.15 Million EUR | 34.89% |
| 2022 Q3 | -40.4 Million EUR | 18.21% |
| 2022 Q2 | -49.4 Million EUR | -1084.72% |
| 2022 Q1 | -4.17 Million EUR | -4443.75% |
| 2022 FY | - EUR | 42.27% |
| 2022 Q4 | -126.38 Million EUR | -212.78% |
| 2021 Q1 | -105.65 Million EUR | -126.73% |
| 2021 Q3 | -136.84 Million EUR | 5.02% |
| 2021 Q2 | -144.08 Million EUR | -36.37% |
| 2021 FY | - EUR | -251.99% |
| 2021 Q4 | 96 Thousand EUR | 100.07% |
| 2020 Q4 | -46.6 Million EUR | -41.71% |
| 2020 Q3 | -32.88 Million EUR | -991.8% |
| 2020 Q2 | -3.01 Million EUR | 85.19% |
| 2020 Q1 | -20.34 Million EUR | 45.56% |
| 2020 FY | - EUR | -20.0% |
| 2019 Q1 | -19.51 Million EUR | 0.0% |
| 2019 Q3 | -17.72 Million EUR | 0.0% |
| 2019 FY | - EUR | -36.42% |
| 2019 Q4 | -37.37 Million EUR | -110.86% |
| 2018 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| BioNTech SE | 1.08 Billion EUR | 121.524% |
| Biotest Aktiengesellschaft | 179 Million EUR | 230.777% |
| Biotest Aktiengesellschaft | 179 Million EUR | 230.777% |
| BRAIN Biotech AG | -2.38 Million EUR | -9706.871% |
| Formycon AG | 81.05 Million EUR | 388.811% |
| Heidelberg Pharma AG | -18.7 Million EUR | -1151.392% |
| Medigene AG | -14.58 Million EUR | -1505.005% |